Back to Agenda
Session 8 Track 2: The Power of Plain Language: How to Create Clear and Understandable Clinical Trial Communications
Session Chair(s)
Sudipta Chakraborty, PhD
Clinical Trial Transparency Strategy Lead
Biogen, United States
With the implementation of recent regulations, the role of plain language in communicating clinical trial information to patients, the public, and regulators has risen to the forefront of transparency and disclosure commitments. From plain language summaries of results and of publications to the new kid on the block (plain language protocol synopses), medical writers must be equipped with the knowledge and skill set to translate technical information into plain language that serves a variety of audiences. In this session, we will explore the ways to effectively produce plain language documents that are fit-for-purpose. Attendees will learn key health literacy principles that highlight the difference between writing for patients and writing for regulators, including challenges in explaining complex ideas like benefit and risk to a lay audience. Then, we will dive into recent updates to regulatory guidances related to informed consent forms (ICFs). This will include tips and tricks to transform ICFs from a legal formality to a meaningful and understandable document that builds trust and empowers patients at the start of their clinical trial journey. Finally, the session will conclude with practical strategies to support the integration of health literacy best practices into the creation of any participant-facing material, as well as an introduction to select resources that advance clear clinical research messaging. Overall, this session aims to empower medical writers with the understanding and skill set required to produce clear, meaningful, and patient-centered clinical trial communications.
Learning Objective : - Describe key health literacy principles that aim to improve the understanding of clinical trial information
- Discuss how to employ best practices that integrate patient perspectives and readability improvements into documents
- Apply the updated FDA guidance on informed consent documents in a way that positively impacts clinical trial development
- Identify supportive resources that advance the communication of clear clinical research information
Speaker(s)
Communicating with Patients: Challenges and Considerations
Lisa Chamberlain-James, PhD
Trilogy Writing & Consulting, United Kingdom
Senior Partner
Revolutionizing Informed Consent: Empowering Medical Writers to Drive Patient-Centered Change
Marialena Davis, PhD, MS
Aroga Biosciences, United States
Regulatory Medical Writer
Integrating Health Literacy Concepts into Materials for Participants: Strategies and Resources
Sylvia Baedorf Kassis, MPH
MRCT Center of Brigham and Women's Hospital and Harvard, United States
Program Director
Have an account?